The estimated Net Worth of Charles Mc Kenney is at least $472 millier dollars as of 1 October 2014. Charles Kenney owns over 2,500 units of Arrowhead Pharmaceuticals stock worth over $412,937 and over the last 20 years Charles sold ARWR stock worth over $58,690.
Sign up
Charles Kenney ARWR stock SEC Form 4 insiders trading
Charles has made over 16 trades of the Arrowhead Pharmaceuticals stock since 2007, according to the Form 4 filled with the SEC. Most recently Charles exercised 2,500 units of ARWR stock worth $12,975 on 1 October 2014.
The largest trade Charles's ever made was exercising 22,000 units of Arrowhead Pharmaceuticals stock on 9 June 2014 worth over $52,580. On average, Charles trades about 1,074 units every 83 days since 2004. As of 1 October 2014 Charles still owns at least 19,720 units of Arrowhead Pharmaceuticals stock.
You can see the complete history of Charles Kenney stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Charles Kenney's mailing address?
Charles's mailing address filed with the SEC is 1118 EAST GREEN STREET, , PASADENA, CA, 91106.
Insiders trading at Arrowhead Pharmaceuticals
Over the last 21 years, insiders at Arrowhead Pharmaceuticals have traded over $129,489,075 worth of Arrowhead Pharmaceuticals stock and bought 176,205 units worth $991,784 . The most active insiders traders include David M Knott, Christopher Richard Anzalone et Kenneth Allen Myszkowski. On average, Arrowhead Pharmaceuticals executives and independent directors trade stock every 38 days with the average trade being worth of $868,068. The most recent stock trade was executed by Tracie Oliver on 2 July 2024, trading 9,394 units of ARWR stock currently worth $237,480.
What does Arrowhead Pharmaceuticals do?
arrowhead pharmaceuticals is a clinical stage, nasdaq listed (ticker arwr) company developing medicines that treat intractable diseases by silencing the genes that cause them. using a broad portfolio of rna chemistries and efficient modes of delivery, our therapies trigger the rna interference mechanism to induce rapid, deep and durable knockdown of target genes. rna interference, or rnai, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. our rnai-based therapeutics are at the leading edge of genetic-based therapy with the potential to bring life changing treatments for patients. our targeted rnai molecule (trimtm) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. the trim platform builds on more than a decade of work on actively targeted drug delivery and offers several advantages including simplified manufacturing
What does Arrowhead Pharmaceuticals's logo look like?
Complete history of Charles Kenney stock trades at Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals executives and stock owners
Arrowhead Pharmaceuticals executives and other stock owners filed with the SEC include:
-
Christopher Anzalone,
President, Chief Executive Officer, Director -
Kenneth Myszkowski,
Chief Financial Officer -
Dr. Christopher R. Anzalone,
CEO, Pres & Director -
Patrick O'Brien,
General Counsel -
Kenneth A. Myszkowski,
Chief Financial Officer -
Dr. Javier San Martin M.D.,
Chief Medical Officer -
Dr. Javier San Martin,
Chief Medical Officer -
Douglass Given,
Chairman of the Board -
Michael Perry,
Lead Independent Director -
James Hassard,
Chief Commercial Officer -
Dr. Bruce D. Given,
Advisor -
William Waddill,
Independent Director -
Mauro Ferrari,
Independent Director -
Vincent Anzalone,
IR Contact Officer -
Oye Olukotun,
Independent Director -
Marianne De Backer,
Independent Director -
Javier San Martin,
Chief Medical Officer -
James Hassard,
Chief Commercial Officer -
Curt Bradshaw,
Chief Scientific Officer -
Dr. Mark Seefeld,
Head of Toxicology & VP -
Dr. James C. Hamilton,
Sr. VP of Discovery & Translational Medicine -
Patrick O'Brien,
Chief Compliance Officer, Gen. Counsel & Corp. Sec. -
Howard Lovy,
Director of Communications -
Jane Davidson,
Head of HR & Admin., VP and Corp. Sec. -
Dr. Mark M. Davis,
Founder and Founder & Director of Insert Therapeutics Inc & Calando -
Bruce D Given,
Chief Operating Officer -
Edward W Frykman,
Director -
David M Knott,
10% owner -
Douglas B Given,
Director -
David L. Lewis,
Chief Scientific Officer -
Joseph Theodore Iii Kingsley,
Chief Financial Officer -
Zhen Li,
Snr. VP, Chem and Non-Clin Dev -
Peter Brian Leone,
VP, Strategy & Program Mgmt -
Victoria Vakiener,
Director -
Leon Ekchian,
President -
Marshall Robert Ching,
10% owner -
James M Jr Phillips,
Secretary -
Charles Mc Kenney,
Director -
R Bruce Stewart,
President -
Leroy T Rahn,
Director -
Paul Clayton Mc Donnel,
Chief Financial Officer -
James C Hamilton,
Chief Discovery/Trans Medicine -
Hongbo Lu,
Director -
Tracie Oliver,
Chief Commercial Officer